Show simple item record

dc.contributor.authorLappegård, Knut Tore
dc.contributor.authorPop-Purceleanu, Monica
dc.contributor.authorvan Heerde, Waander L.
dc.contributor.authorSexton, Joseph
dc.contributor.authorTendolkar, Indira
dc.contributor.authorPop, Gheorghe A.
dc.date.accessioned2014-03-20T15:23:01Z
dc.date.available2014-03-20T15:23:01Z
dc.date.issued2013
dc.description.abstractBackground: Atrial fibrillation (AF) is associated with increased mortality and morbidity, including risk for cerebral macro- and microinfarctions and cognitive decline, even in the presence of adequate oral anticoagulation. AF is strongly related to increased inflammatory activity whereby anti-inflammatory agents can reduce the risk of new or recurrent AF. However, it is not known whether anti-inflammatory therapy can also modify the deterioration of neurocognitive function in older patients with AF. In the present study, older patients with AF were treated with intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg, or placebo. We examined the relationship between neurocognitive functions and inflammatory burden. Findings: Analysis of inflammatory markers revealed significant reductions in high sensitivity C-reactive protein (hs-CRP), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor antagonist (IL-1RA), interleukin (IL)-9, IL-13 and IL-17, and interferon-γ (IFNγ) in the treatment group compared to placebo. Reduction in plasma concentration of IL-1RA, IL-2, IL-9 and IL-12, and macrophage inflammatory protein-1β (MIP-1β) correlated significantly with improvement in the neurocognitive functions memory and speed. Loss of volume in amygdala and hippocampus, as determined by magnetic resonance imaging (MRI), was reduced in the treatment arm, statistically significant for left amygdala. Conclusions: Anti-inflammatory therapy through intensive lipid-lowering treatment with atorvastatin 40 mg and ezetimibe 10 mg can modify the deterioration of neurocognitive function, and the loss of volume in certain cerebral areas in older patients with AF.en
dc.identifier.citationJournal of Neuroinflammation (2013), vol. 10:78en
dc.identifier.cristinIDFRIDAID 1045201
dc.identifier.doihttp://dx.doi.org/10.1186/1742-2094-10-78
dc.identifier.issn1742-2094
dc.identifier.urihttps://hdl.handle.net/10037/6020
dc.identifier.urnURN:NBN:no-uit_munin_5700
dc.language.isoengen
dc.publisherBioMed Centralen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Neurology: 752en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752en
dc.titleImproved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapyen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record